IFNAR1 and neoplasm: VSVmIFNβ administration provided a selective advantage for IFNAR KO CD8 CAR T over WT CD8 CAR T cells in both the spleen and tumor, and the magnitude of the enrichment was enhanced in lymphodepleted animals.